Balt Receives CE Mark and Performs First-in-Man for the Silk Vista Flow Diverter

Balt ( www.balt-corp.com ) announced today it has received CE Mark Approval for its Silk Vista flow diverting stent to treat patients with unruptured intracranial aneurysms, enabling commercialization in over 30 countries in and around the European Union.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, July 8, 2020
Information
Tags: 
Health, Medical devices, Surgery, Other Health, General Health, Radiology, Biotechnology, Medical specialties, Vascular diseases, Medicine, Neurosurgery, Cerebrovascular diseases, Flow diverter, Prosthetics, Aneurysm, Intracranial aneurysm, Silk, Vista
Geotags: 
France, Europe
⚠generated by AI ↴
Summary
Key Points: 
  • Balt ( www.balt-corp.com ) announced today it has received CE Mark Approval for its Silk Vista flow diverting stent to treat patients with unruptured intracranial aneurysms, enabling commercialization in over 30 countries in and around the European Union.
  • The Silk Vista device is designed for predictable and accurate deployment, as well as high visibility under angiography.
  • It joins the lower profile Silk Vista baby flow diverter, which received CE Mark in 2018.
  • The Silk Vista is an exceptional flow diverter, and we believe its elegant design and ease-of-use will lead to its rapid clinical adoption in treating aneurysms.


Balt (www.balt-corp.com) announced today it has received CE Mark Approval for its Silk Vista flow diverting stent to treat patients with unruptured intracranial aneurysms, enabling commercialization in over 30 countries in and around the European Union.

Flow diverters are intended to divert blood flow away from an aneurysm, allowing the aneurysm to heal and reducing the risk of aneurysm rupture. The Silk Vista device is designed for predictable and accurate deployment, as well as high visibility under angiography. It joins the lower profile Silk Vista baby flow diverter, which received CE Mark in 2018.

“Balt introduced the Silk Vista baby two years ago, a first-in-class flow diverter device for the treatment of distal aneurysms with the benefits of excellent visibility and device deployment,” said Vitor Mendes Pereira, M.D., an Endovascular Neurosurgeon and Professor of Medical Imaging and Surgery at the University of Toronto. “Now, with Silk Vista, Balt has provided physicians the same outstanding deliverability and visibility for the treatment of aneurysms arising off of neurovascular vessels 3.5 mm and larger, while managing to keep the device compatible with a very low profile .021” microcatheter.” Dr. Mendes Pereira performed the First-in-Man case of Silk Vista in Toronto in June.

Balt CEO Pascal Girin commented, “Balt has provided physicians for decades with unique, life-saving products to treat patients with neurovascular conditions and has been a pioneer in flow diversion technologies. The Silk Vista is an exceptional flow diverter, and we believe its elegant design and ease-of-use will lead to its rapid clinical adoption in treating aneurysms.”

According to the Brain Aneurysm Foundation, ruptured brain aneurysms are fatal in about 50% of cases. Of those who survive, about 66% suffer some permanent neurological deficit. There are almost 500,000 deaths worldwide each year caused by ruptured brain aneurysms1.

About Balt:

Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening neurovascular conditions such as ischemic strokes, aneurysms and arteriovenous malformations. A pioneer in the neurovascular field, Balt designs, manufactures and distributes the broadest portfolio of products in the neurovascular space and is now focused on expanding its geographic presence in both the USA and China.

1https://bafound.org/about-brain-aneurysms/brain-aneurysm-basics/brain-aneurysm-statistics-and-facts/

Copyright: 
Copyright Business Wire 2020